Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01196182 · ClinicalTrials.gov registry record
Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)
A clinical trial of Congenital Heart Defects, sponsored by Children's Hospital Medical Center, Cincinnati.
- Active
- Registry status
- 32,000
- Enrollment target
- 15
- Study locations
NCT01196182: Active study of Congenital Heart Defects, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT01196182 is a study of Congenital Heart Defects that is active but no longer recruiting, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 32,000 participants, above the 747-participant average among 3 other Congenital Heart Defects trials with a reported enrollment target (4184% higher). The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01196182, a study of Congenital Heart Defects, is active but no longer recruiting, sponsored by Children's Hospital Medical Center, Cincinnati.
- ACTIVE NOT RECRUITING
- Registry status
- 32,000 participants
- Enrollment target
- 15
- Study locations
Study Summary
Congenital heart defects (CHD) are the most common major human birth malformation, affecting \~8 per 1,000 live births. CHD are associated with significant morbidity and mortality, and are second only to infectious diseases in contributing to the infant mortality rate. Current understanding of the etiology of pediatric cardiovascular disorders is limited. The Congenital Heart Disease GEnetic NEtwork Study (CHD GENES) is a multi-center, prospective observational cohort study. Participants will be recruited from the Pediatric Cardiac Genomics Consortium's (PCGC) centers of the NHLBI-sponsored Bench to Bassinet (B2B) Program. Biological specimens will be obtained for genetic analyses, and phenotype data will be collected by interview and from medical records. State-of-the-art genomic technologies will be used to identify common genetic causes of CHD and genetic modifiers of clinical outcome. To accomplish this, the PCGC will develop and maintain a biorepository of specimens (DNA) and genetic data, along with detailed, phenotypic and clinical outcomes data in order to investigate relationships between genetic factors and phenotypic and clinical outcomes in congenital heart disease.
Conditions Studied
Study Locations (15)
New York
- Cohen Children's Medical Center New York - New Hyde Park
- Mount Sinai School of Medicine - New York
- Columbia University Medical Center - New York
- University of Rochester - Rochester
California
- Children's Hospital Los Angeles - Los Angeles
- Stanford University - Palo Alto
- University of California, San Francisco - San Francisco
Massachusetts
- Brigham & Women's Hospital - Boston
- Children's Hospital Boston - Boston
Connecticut
- Yale University - New Haven
Georgia
- Children's Healthcare of Atlanta - Atlanta
Michigan
- University of Michigan Health - Ann Arbor
Pennsylvania
- Children's Hospital Philadelphia - Philadelphia
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32,000 participants |
| Start Date | 2010-11-15 |
| Est. Completion | 2032-12 |
What the registry record for NCT01196182 still lists
NCT01196182 is an observational study that tracks outcomes without assigning an intervention. Its 32,000 participants enrollment target places it among the larger protocols in the corpus, above the 747-participant average among 3 other Congenital Heart Defects trials with a reported enrollment target (4184% higher).
The record links to 1 condition, with Congenital Heart Defects appearing as the primary indexed condition, and to 0 interventions.
NCT01196182 lists 15 locations in 9 states (New York, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT01196182 about?
NCT01196182 is a clinical study titled "Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)". Congenital heart defects (CHD) are the most common major human birth malformation, affecting \~8 per 1,000 live births. CHD are associated with significant morbidity and mortality, and are second only to infectious diseases in contributing to the infant mortality rate. Current understanding of the e...
What is the current status of trial NCT01196182?
This trial is currently active not recruiting. The enrollment target is 32,000 participants. The study started on 2010-11-15. Estimated completion is 2032-12.
What conditions does trial NCT01196182 study?
This clinical trial studies the following conditions: Congenital Heart Defects.
Who is sponsoring clinical trial NCT01196182?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01196182 being conducted?
This trial has 15 study locations across California, Connecticut, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Defects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07282665 · 32,000 participants · Phase 3
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
- NCT04477928 · 33,000 participants
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
- NCT06145724 · 33,183 participants · NA
EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI